Dr David Bull is Director of Research for Duchenne UK. David spent 16 years as a research scientist at GlaxoSmithKline. His initial training was in neuroscience, studying novel treatments for Parkinson’s Disease and Schizophrenia, David then led the research team looking into the molecular biology of 5-HT receptors in terms of treating migraine.

David then moved into science development in the UK and USA and led the UK Learning & Development team, subsequently becoming VP Leadership & Organisation Development for GSK International.